TY - JOUR
T1 - Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation
AU - Rosti, Vittorio
AU - Villani, Laura
AU - Riboni, Roberta
AU - Poletto, Valentina
AU - Bonetti, Elisa
AU - Tozzi, Lorenzo
AU - Bergamaschi, Gaetano
AU - Catarsi, Paolo
AU - Dallera, Elena
AU - Novara, Francesca
AU - Massa, Margherita
AU - Campanelli, Rita
AU - Fois, Gabriela
AU - Peruzzi, Benedetta
AU - Lucioni, Marco
AU - Guglielmelli, Paola
AU - Pancrazzi, Alessandro
AU - Fiandrino, Giacomo
AU - Zuffardi, Orsetta
AU - Magrini, Umberto
AU - Paulli, Marco
AU - Vannucchi, Alessandro M.
AU - Barosi, Giovanni
PY - 2013/1/10
Y1 - 2013/1/10
N2 - Increased microvessel density contributes to abnormal BM and spleen microenvironment in myelofibrosis (MF). Taking advantage of the JAK2V617F mutation as a marker of malignancy, in the present study, we investigated whether splenic endothelial cells (ECs) obtained from capillaries by laser microdissection or from fresh spleen tissue by cell culture or cell sorting harbored such mutation in patients bearing the mutation in their granulocytes and undergoing splenectomy for therapeutical reasons. To extend the analysis to the ECs of large vessels, endothelial tissue from the splenic vein was also studied.We found JAK2V617F+ ECs in 12 of 18 patients also bearing the mutation in their granulocytes. In 3 patients, the mutation was found in at least 2 different EC samples obtained by laser microdissection, cell culture, or cell sorting. The mutation was detected in the splenic vein ECs of 1 of 6 patients investigated. In conclusion, we provide evidence that some ECs from the spleen and splenic veins of patients with MF bear the JAK2V617F mutation. We suggest that splenic ECs are involved in the process of malignant transformation in MF.
AB - Increased microvessel density contributes to abnormal BM and spleen microenvironment in myelofibrosis (MF). Taking advantage of the JAK2V617F mutation as a marker of malignancy, in the present study, we investigated whether splenic endothelial cells (ECs) obtained from capillaries by laser microdissection or from fresh spleen tissue by cell culture or cell sorting harbored such mutation in patients bearing the mutation in their granulocytes and undergoing splenectomy for therapeutical reasons. To extend the analysis to the ECs of large vessels, endothelial tissue from the splenic vein was also studied.We found JAK2V617F+ ECs in 12 of 18 patients also bearing the mutation in their granulocytes. In 3 patients, the mutation was found in at least 2 different EC samples obtained by laser microdissection, cell culture, or cell sorting. The mutation was detected in the splenic vein ECs of 1 of 6 patients investigated. In conclusion, we provide evidence that some ECs from the spleen and splenic veins of patients with MF bear the JAK2V617F mutation. We suggest that splenic ECs are involved in the process of malignant transformation in MF.
UR - http://www.scopus.com/inward/record.url?scp=84872353179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872353179&partnerID=8YFLogxK
U2 - 10.1182/blood-2012-01-404889
DO - 10.1182/blood-2012-01-404889
M3 - Article
C2 - 23129323
AN - SCOPUS:84872353179
VL - 121
SP - 360
EP - 368
JO - Blood
JF - Blood
SN - 0006-4971
IS - 2
ER -